Streetbeat News

Stock Prices

PAM

Pampa Energia (NYSE:PAM) reported a Q4 2023 GAAP EPS of $(2.900) and sales of $362.000M, missing the analyst consensus estimate of $261.541B by 99.86%. This represents a 19.20% decrease in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 10:09 pm

EBS

Emergent BioSolutions Inc (NYSE:EBS) reported Q4 losses of 77 cents per share, missing analyst estimates, and quarterly sales of $276.6 million, below expectations. Sales from Narcan Nasal Spray increased by 22% year-over-year. The company amended its credit agreement for more flexible terms and provided an optimistic revenue outlook for Q1 and the fiscal year, despite acknowledging short-term challenges.

Portfolio Pulse from Erica Kollmann

March 06, 2024 | 10:02 pm

BENF

Beneficient (NASDAQ:BENF) has announced a new liquidity transaction with ff Venture Capital, involving the financing of liquidity transactions for three separate funds managed by ff Venture Capital. This deal, subject to shareholder approval, could increase Ben's loan portfolio collateral by up to $121.5 million. The transactions are expected to close in Q3 2024 and involve the issuance of Resettable Convertible Preferred Stock to limited partners participating in the deal. This move is part of Beneficient's broader strategy to provide liquidity solutions to the alternative asset market.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 10:02 pm

GSK

PFE

ViiV Healthcare, majorly owned by GSK with Pfizer and Shionogi as shareholders, announced interim phase 3 trial results showing its injectable HIV treatment, Cabenuva, outperforms daily oral therapy in maintaining viral suppression in patients with ART adherence challenges. The study highlighted superior efficacy of the long-acting injectable over standard oral care, despite similar rates of adverse events. Pfizer's stock saw a 4.26% increase to $27.19 following the news.

Portfolio Pulse from Vandana Singh

March 06, 2024 | 10:00 pm

BAYRY

BAYZF

BOLD

Boundless Bio, a biotechnology company, has filed for an Initial Public Offering (IPO) and plans to list its common stock on the Nasdaq under the symbol 'BOLD'. Bayer AG (BAYRY) and its subsidiary Bayerische Motoren Werke AG (BAYZF) are mentioned in relation to their potential interest or involvement in Boundless Bio's market sector.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 9:59 pm

LYT

Lytus Technologies' stock price increased following the announcement of the launch of Lytus Cloud, indicating positive market reception to the company's new service offering.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 9:55 pm

TPVG

TriplePoint Venture Growth (TPVG) shares are trading lower due to the company reporting worse-than-expected Q4 financial results.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 9:54 pm

INFN

Infinera's stock is trading lower following the announcement of its preliminary financial results for the fourth quarter.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 9:53 pm

RSI

Rush Street Interactive's shares surged following the announcement of its Q4 financial results, which exceeded expectations. Additionally, the company provided a revenue forecast for 2024 that surpasses analyst estimates.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 9:52 pm

SLNO

Soleno Therapeutics shares are trading lower following the announcement of their Q4 financial results.

Portfolio Pulse from Benzinga Newsdesk

March 06, 2024 | 9:51 pm